|
1
|
Peng L, Li J, Wu J, Xu B, Wang Z, Giamas
G, Stebbing J and Yu Z: A Pan-Cancer Analysis of SMARCA4
alterations in human cancers. Front Immunol. 12:7625982021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kakkar A, Ashraf SF, Rathor A, Adhya AK,
Mani S, Sikka K and Jain D: SMARCA4/BRG1-Deficient Sinonasal
Carcinoma. Arch Pathol Lab Med. 146:1122–1130. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nambirajan A, Singh V, Bhardwaj N, Mittal
S, Kumar S and Jain D: SMARCA4/BRG1-Deficient non-small cell lung
carcinomas: A case series and review of the literature. Arch Pathol
Lab Med. 145:90–98. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ota T, Ishikawa T, Yasuda R, Yasuda T,
Okayama T, Inoue K, Dohi O, Yoshida N, Kamada K, Uchiyama K, et al:
The first case of SMARCA4-deficient sarcoma of stomach. Clin J
Gastroenterol. 15:531–536. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duan H, Gao W, Wang L, Cao F and Teng L:
Undifferentiated colonic neoplasm with SMARCA4 germline gene
mutation and loss of SMARCA4 protein expression: A case report and
literature review. Diagn Pathol. 16:302021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang R, Chen L, Pan C and Fang X:
SMARCA4-deficient dedifferentiated endometrioid carcinoma: A case
report. Asian J Surg. 46:5484–5485. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Michel BC, D'Avino AR, Cassel SH,
Mashtalir N, McKenzie ZM, McBride MJ, Valencia AM, Zhou Q, Bocker
M, Soares LMM, et al: A non-canonical SWI/SNF complex is a
synthetic lethal target in cancers driven by BAF complex
perturbation. Nat Cell Biol. 20:1410–1420. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim SY, Shen Q, Son K, Kim HS, Yang HD, Na
MJ, Shin E, Yu S, Kang K, You JS, et al: SMARCA4 oncogenic
potential via IRAK1 enhancer to activate Gankyrin and AKR1B10 in
liver cancer. Oncogene. 40:4652–4662. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Guerrero-Martínez JA and Reyes JC: High
expression of SMARCA4 or SMARCA2 is frequently associated with an
opposite prognosis in cancer. Sci Rep. 8:20432018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Witkowski L, Carrot-Zhang J, Albrecht S,
Fahiminiya S, Hamel N, Tomiak E, Grynspan D, Saloustros E, Nadaf J,
Rivera B, et al: Germline and somatic SMARCA4 mutations
characterize small cell carcinoma of the ovary, hypercalcemic type.
Nat Genet. 46:438–443. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kolin DL, Quick CM, Dong F, Fletcher CDM,
Stewart CJR, Soma A, Hornick JL, Nucci MR and Howitt BE:
SMARCA4-deficient uterine sarcoma and undifferentiated endometrial
carcinoma are distinct clinicopathologic entities. Am J Surg
Pathol. 44:263–270. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Karanian-Philippe M, Velasco V, Longy M,
Floquet A, Arnould L, Coindre JM, Le Naoures-Méar C, Averous G,
Guyon F, MacGrogan G and Croce S: SMARCA4 (BRG1) loss of expression
is a useful marker for the diagnosis of ovarian small cell
carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): A
comprehensive analysis of 116 rare gynecologic tumors, 9 soft
tissue tumors, and 9 melanomas. Am J Surg Pathol. 39:1197–1205.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin DI, Allen JM, Hecht JL, Killian JK,
Ngo NT, Edgerly C, Severson EA, Ali SM, Erlich RL, Ramkissoon SH,
et al: SMARCA4 inactivation defines a subset of undifferentiated
uterine sarcomas with rhabdoid and small cell features and germline
mutation association. Mod Pathol. 32:1675–1687. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Azzalini E, Stanta G, Canzonieri V and
Bonin S: Overview of tumor heterogeneity in high-grade serous
ovarian cancers. Int J Mol Sci. 24:150772023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Brambs CE, Höhn AK, Klagges S, Gläser A,
Taubenheim S, Dornhöfer N, Einenkel J, Hiller GGR and Horn LC:
Clinico-pathologic characteristics and prognostic factors of
ovarian carcinoma with different histologic subtypes-A benchmark
analysis of 482 cases. Pathol Res Pract. 233:1538592022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Connor YD, Miao D, Lin DI, Hayne C, Howitt
BE, Dalrymple JL, DeLeonardis KR, Hacker MR, Esselen KM and Shea M:
Germline mutations of SMARCA4 in small cell carcinoma of the ovary,
hypercalcemic type and in SMARCA4-deficient undifferentiated
uterine sarcoma: Clinical features of a single family and
comparison of large cohorts. Gynecol Oncol. 157:106–114. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu B and Shi H: An in-depth look at small
cell carcinoma of the ovary, hypercalcemic type (SCCOHT): Clinical
implications from recent molecular findings. J Cancer. 10:223–237.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao J, Fan R, Chen D, Hou J, Chen H and Lu
M: Pathological characteristics and immune microenvironment of
SMARCA4-deficient undifferentiated uterine sarcoma. Diagn Pathol.
18:622023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Witkowski L, Goudie C, Ramos P, Boshari T,
Brunet JS, Karnezis AN, Longy M, Knost JA, Saloustros E, McCluggage
WG, et al: The influence of clinical and genetic factors on patient
outcome in small cell carcinoma of the ovary, hypercalcemic type.
Gynecol Oncol. 141:454–460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shinno Y, Yoshida A, Masuda K, Matsumoto
Y, Okuma Y, Yoshida T, Goto Y, Horinouchi H, Yamamoto N, Yatabe Y
and Ohe Y: Efficacy of immune checkpoint inhibitors in
SMARCA4-Deficient thoracic tumor. Clin Lung Cancer. 23:386–392.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bhat V, Koneru M, Knapp K, Joneja U,
Morrison J and Hong YK: Identification and treatment of SMARCA4
deficient poorly differentiated gastric carcinoma. Am Surg.
89:4987–4989. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang P, Xiong F, Lin Y, Liang P and Tang
C: Effectiveness of tislelizumab when combined with etoposide and
carboplatin in patients with SMARCA4-deficient undifferentiated
thoracic tumor: A case report. Transl Cancer Res. 12:1041–1048.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kunimasa K, Okami J, Takenaka S, Honma K,
Kukita Y, Nagata S, Kawamura T, Inoue T, Tamiya M, Kuhara H, et al:
Conversion surgery for advanced thoracic SMARCA4-Deficient
undifferentiated tumor with atezolizumab in combination with
bevacizumab, paclitaxel, and carboplatin treatment: A case report.
JTO Clin Res Rep. 2:1002352021.PubMed/NCBI
|
|
24
|
Kurokawa M, Shimizuguchi T, Ito K, Takao
M, Motoi T, Taguchi A, Yasugi T and Karasawa K: Notable Response of
SMARCA4-Deficient undifferentiated uterine sarcoma to palliative
radiation therapy. Adv Radiat Oncol. 6:1007282021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Romero OA, Vilarrubi A, Alburquerque-Bejar
JJ, Gomez A, Andrades A, Trastulli D, Pros E, Setien F, Verdura S,
Farré L, et al: SMARCA4 deficient tumours are vulnerable to
KDM6A/UTX and KDM6B/JMJD3 blockade. Nat Commun. 12:43192021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qian B, Leng W, Yan Z, Lu J, Chen S, Yi H
and Jiang Z: Clinical Benefit With PARP inhibitor for pathogenic
germline FANCA-Mutated relapsed epithelial ovarian cancer: A case
report. Front Oncol. 12:7785452022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liang X, Gao X, Wang F, Li S, Zhou Y, Guo
P, Meng Y and Lu T: Clinical characteristics and prognostic
analysis of SMARCA4-deficient non-small cell lung cancer. Cancer
Med. 12:14171–14182. 2023. View Article : Google Scholar : PubMed/NCBI
|
